Related stories
[ad_1]
The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company’s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said
[ad_2]
Source link
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Latest stories
Each template in our ever growing studio library can be added and moved around within any page effortlessly with one click.
© 2023 Finnoexpert. All Rights Reserved. Made with Team Finno.
